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A B S T R A C T   
Background: Adherence to therapy has been reported worldwide as a major problem, and that is particularly 
relevant on inhaled therapy for Asthma and Chronic Obstructive Pulmonary Disease (COPD), considering its 
barriers and features. We reviewed the global literature reporting the main determinants for adherence on these 
patients. 
Methods: Searches were made using the Cochrane Library, MEDLINE, EMBASE and ISI Web of Science databases. 
Analytical, observational and epidemiological studies (cohort, case-control and cross-sectional studies) were 
included, reporting association between any type of determinant and the adherence for inhaler therapy on 
Asthma or COPD. Random-effects meta-analysis were used to summarise the numerical effect estimates. 
Results: 47 studies were included, including a total of 54.765 participants. In meta-analyses, the significant 
determinants of adherence to inhaled therapy were: older age [RR = 1.07 (1.03–1.10); I2 = 94; p < 0.0001] good 
disease knowledge/literacy [RR = 1.37 (1.28–1.47); I2 = 14; p = 0.33]; obesity [RR = 1.30 (1.12–1.50); I2 = 0; p 
= 0.37]; good cognitive performance [RR = 1.28 (1.17–1.40); I2 = 0; p = 0.62]; higher income [RR = 1.63 
(1.05–2.56); I2 = 0; p = 0.52]; being employed [RR = 0.87 (0.83–0.90); I2 = 0; p = 0.76] and using multiple 
drugs/inhalers [RR = 0.81 (0.79–0.84); I2 = 0; p = 0.80]. Overall, the strength of the underlying evidence was 
only low to moderate. 
Conclusions: Many determinants may be associated to patient’s adherence, and personalised interventions should 
be taken in clinical practice to address it by gaining an understanding of their individual features.   
1. Introduction 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are 
chronic inflammatory disorders of the airways characterised by airway 
obstruction and affects approximately 10% of the global population. The 
most recent recommended therapy according to major guidelines is 
through inhaled therapy [1,2]. 
According to previous reports [3] the concept of adherence empha-
sizes the need for agreement and can be defined as the extent to which 
the patient’s behavior matches the agreed recommendations from the 
prescriber and the prescription. To achieve optimal adherence, a patient 
must undertake a sequence of key steps (initiation, implementation and 
persistence/discontinuation), and each one of them has specific related 
features and may be influenced by different factors [4,5]. Adherence to 
pharmacological treatment is, therefore, a key factor to control chronic 
respiratory diseases. However, many studies reveal poor adherence to 
the therapy in all pathways, either oral or inhaled, which leads to poor 
disease control. This is particularly relevant on asthma and COPD 
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Covilhã, Portugal. 
E-mail address: tiago.maricoto@gmail.com (T. Maricoto).  
Contents lists available at ScienceDirect 
Respiratory Medicine 
journal homepage: www.elsevier.com/locate/rmed 
https://doi.org/10.1016/j.rmed.2021.106724 
Received 25 September 2021; Received in revised form 15 December 2021; Accepted 19 December 2021   
Respiratory Medicine 191 (2022) 106724
2
patients, considering that, to achieve the best therapeutic efficacy, pa-
tients must properly adhere to the prescribed regiment, but also, use 
their inhalers correctly and with appropriate inhalation technique [6,7]. 
In fact, inhaler adherence and inhalation technique are close, but quite 
independent concepts, and different factors may influence each one of 
them. Nevertheless, some studies highlight the role of inhaler poor 
adherence as it may contribute to inhalers misuse and poor inhalation 
technique [8]. These patients are exposed to higher risks of adverse 
outcomes and to significant morbidity and mortality. 
Non-adherence to inhaled therapy may be associated with several 
factors, either intentional (linked to patients willing to take it or even to 
patients’ beliefs) or unintentional (linked to patients sociodemographic 
and other objective features, and that may affect their ability to use 
inhalers properly and without inhaler technique errors). Some studies 
have pointed out the main factors of therapeutic adherence, such as its 
associated costs, patient’s educational level, age, adverse side effects, 
social and economic issues, satisfaction with treatment, symptomatic 
control and improvement in lung function, complexity of inhaler func-
tioning, among others [9]. In fact, non-adherence may be related to 
factors at several levels, such as the patient level (including intentional 
and non-intentional drivers that affect patient’s motivation and ability 
to adhere), the patient-provider level (related to communication and to 
the prescribing process) and the healthcare system level (related to the 
access to medication) [10,11]. 
Inhaled therapy presents significant levels of non-adherence [12] 
leading to increased exacerbations and consequently to increased risk 
for hospital admissions. There is still an ongoing discussion and con-
troversy, upon which predictors are most relevant to inhaler adherence 
[13]. Previous works conducted with asthma patients identified inten-
tional [14] and unintentional [15] determinants, but found inconsistent 
results, mainly due to the heterogeneity of instruments and operational 
measures of adherence, as well as patient’s characteristics. Also, a pre-
vious systematic review addressing interventions to improve adherence 
pointed out the same limitations [16]. Furthermore, previous systematic 
reviews focused mostly on asthma patients, but non-adherence to 
inhaled therapy equally affects COPD patients, and those also need to be 
addressed in future studies [8,9,13,14,17]. 
A systematic review was performed aiming to assess the most rele-
vant determining factors associated with poor inhaler adherence in pa-
tients with asthma or COPD. 
2. Methods and analysis 
A protocol for this study was developed, registered with the Inter-
national prospective register of systematic reviews (PROSPERO) 
(registration number CRD42020167249) [18]. This review is reported in 
accordance with the PRISMA guidelines for systematic reviews and 
MOOSE guidelines for meta-analysis of observational epidemiological 
studies [19,20]. No modifications were made, compared with the initial 
protocol. 
2.1. Eligibility criteria for study selection 
2.1.1. Participants and study types 
Were included all studies that had participants of any age, with 
diagnosed of Asthma and/or COPD, designed as observational and 
analytical epidemiological studies, including cohort, case-control and 
cross-sectional studies. Were excluded discussion papers, non-research 
letters and editorials, randomised control trials, clinical case studies 
and case-series, and animal studies. 
2.1.2. Exposure 
Studies that include any demographic, individual, psychosocial and 
environmental predictors of inhaled therapy adherence were eligible for 
inclusion. 
2.1.3. Study outcomes 
The outcome was the effective adherence to the inhaled therapy, 
measured either on a validated scale or by other mean that the authors 
may have found suitable. 
2.2. Search strategy 
A comprehensive search strategy was developed for retrieving pub-
lished and unpublished studies on the topic (online supplementary Ap-
pendix S1 - “Search strategy”). Searches were made in the Cochrane 
Library, MEDLINE, EMBASE and ISI Web of Science. Search dates were 
from inception up to October 2020. The references in all eligible studies 
were reviewed to identify additional studies. No language restrictions 
were imposed in the searches and translations were made where 
necessary. 
2.3. Selection process 
Papers retrieved from the databases were exported to the online 
reference management software Rayyan® (available at rayyan.qcri.org). 
Two reviewers (CM and TM) independently selected the articles ac-
cording to the defined criteria and applied the following screening 
stages: cleaning of duplicated articles, selection of articles according to 
eligibility criteria and by reading the title and abstract, and selection of 
articles according to full text reading. All disagreements were resolved 
through discussion or arbitrated by a third review author (JAS). 
Reasons for excluding articles during the full text screening were 
noted and indicated in PRISMA diagram (Fig. 1) [21]. 
2.4. Data collection process 
Two authors (CM and TM) collected data from included articles in 
their original presentation and recorded them in a spreadsheet made in 
Microsoft Excel software and tailored to the current systematic review. 
Indirect data from figures and charts was collected, adapting their 
interpretation by consensus, and contacted authors of original articles 
for further information and data when necessary. Any disagreement in 
data collection was resolved through discussion or arbitrated by a third 
review author (JAS). 
2.5. Type of data collected 
The following information from all included studies was collected:  
• Study design, number of participants and their characteristics (age, 
gender, type of diagnosis, years since diagnosis and asthma or COPD 
stage/grade), variables of exposure to determinants/predictors (such 
as smoking, lifestyle habits, environmental exposures, cognitive 
performance, comorbidities such as obesity, diabetes or cancer, 
clinical control, exacerbation history, employment, literacy, educa-
tional level, income, nº of outpatient/regular visits and other psy-
chosocial or objective determinants …), inhalers used (type of 
device, inhaler performance, previous inhaler performance educa-
tion received, type of drugs used), follow-up (in case of cohort 
studies), country of study, year of publication 
• Estimates of the association between parameters of the main de-
terminants/predictors identified and the study outcome (measured 
as hazard ratio, risk ratio, odds ratio, 95% confidence intervals, mean 
and SD). One author (TM) inserted data into Review Manager Soft-
ware (RevMan) (available at http://community.cochrane.org), and 
data were double-checked for correct entry by a second author (CM). 
2.6. Quality assessment 
Two authors (CM, TM) appraised the quality of included studies 
using an adaptation of the GRADE quality assessment tool [22,23]. 
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Different components of each study were appraised, including con-
founding, selection, measurement of exposure, departures from expo-
sure, missing data, measurement of outcomes and reported results. For 
each study, the grading of each individual components and the global 
study rating were assigned categories of risk of bias: low, moderate, 
severe, and critical. The global grading involved taking an average and 
relative weight of all individual components. Any disagreements not 
resolved by discussion were arbitrated by a third reviewer (JAS). 
2.7. Data synthesis 
All variables regarding the determinants and the outcome measure 
were collected in their original status, and the ones considered similar 
enough to be combined in quantitative analysis were used for 
metanalysis. Regarding adherence, all collected studies reported it on a 
continuous or dichotomous format, but only those reporting it as a 
dichotomous variable were able to be included in the metanalysis. It was 
possible to categorize the different methods to measure adherence in 
four main types but not to standardize the different cut-offs that were 
used among the original studies to dichotomize it. Therefore, regarding 
the prevalence of “good adherence” and its association to the potential 
determinants. Raw data was used as it is reported by original studies. 
A descriptive summary of all included studies is presented in order to 
summarise literature. All studies were judged to be reasonably, clinically 
and methodologically heterogeneous. Therefore, meta-analyses were 
performed using random-effects models. The heterogeneity between 
studies was quantified using the I2 statistic. Sensitivity analyses were 
made on the basis of risk of bias in the studies in order to assess the 
robustness of these findings to different assumptions. In the meta- 
analysis, estimates from studies not presented as RRs, were converted 
to RRs using the recently proposed formulae provided by VanderWeele 
et al. [24] Sub-group analyses were performed, for all determinants, 
according to: publication year (by decades), continental region, study 
design (cross-sectional or cohort), risk of bias assessment, study 
dimension/size, diagnosis type (asthma, COPD or both), types of in-
struments to measure adherence (dose counting or eletronically moni-
tored, or via an unspecific self-reported measure, Morisky Medication 
Adherence Scale (MMAS) or Test of Adherence to Inhalers (TAI) and 
study participants mean ages). Publication bias was accessed using 
funnel plots. The meta-analyses were performed using Cochrane Review 
Manager Software© (available at http://community.cochrane.org). The 
PRISMA checklist was followed for reporting of the systematic review. 
3. Results 
3.1. Description of studies 
The research yielded 2306 articles, and, after elimination of dupli-
cates, 1931 remained. From these articles, 1848 were excluded after 
reading title and/or abstract. Thus, 83 studies were obtained, from 
which, after reading the full text, 36 were excluded for several reasons 
(Fig. 1). 
Of the 47 eligible studies [3,25–70], 21 (44.7%) were cross-sectional 
and 26 (55.3%) were cohort studies. A total of 54.765 individuals were 
studied and most (n = 41; 87.2%) were studies in adults. 
Twenty-eight studies (59.6%) included only Asthma patients, and 11 
(23.4%) only COPD patients. Although the majority of studies did not 
report data about disease severity, those that did, included participants 
with moderate and poorly controlled Asthma or COPD. 
Detailed information for all selected studies is available at 
Fig. 1. Flow diagram on search and article inclusion, according to PRISMA statement.  
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supplementary Appendix S3 – “Complete data of selected studies”. 
3.2. Measures of adherence 
Several tools were used to measure adherence to inhaled therapy. 
Most studies (n = 23; 48.9%) used a dose counting or electronically 
monitored systems, while 9 studies (19.2%) used an unspecific self- 
reported measure; 5 (10.6%) used the Morisky Medication Adherence 
Scale (MMAS) and other 5 (10.6%) used the Test of Adherence to In-
halers (TAI). 
Among studies using “dose counting or electronically monitored 
systems”, we found one study measuring adherence through a direct 
dose counting on inhaler (61), the majority using a community or hos-
pital pharmacy electronic record system (47, 48, 56, 44, 65, 28, 39, 37, 
21, 53, 29) and 5 using a smart-inhaler or an electronic monitor attached 
to the inhaler (26, 63, 27, 59, 55). Most of them defined good adherence 
as a dichotomous variable, considering a compliance of at least 70–80% 
among the prescribed days or doses. The exception were 2 studies (37, 
21) that defined the cut-off at 50%, and 2 others (53, 29) that defined it 
as “taking medication in a regular/daily basis”. 3 studies (26, 63, 27) did 
not specified the cut-off criteria used for good adherence. 
All the studies using the Morisky Medication Adherence Scale 
(MMAS) defined adherence using the predefined and validated cut-off 
for a dichotomous variable setting of “good adherence”, although one 
study used de 4-item version (38) and other de 8-item version (43). The 
same coherence was found in studies using Test of Adherence to Inhalers 
(TAI), and studies using Medication Adherence Reporting Scale (MARS), 
except for 2 studies that used the 10-item version of MARS (49, 57). 
Several studies did not report any specific and objective measure of 
adherence, resorting to patients self-reporting. Nevertheless, some of 
them (31, 32, 50) defined good adherence if participants reported a 
compliance of at least 80% among the prescribed days or doses, or 80% 
positive answers to some type of unstandardized questionnaire. 
3.3. Risk of bias in included studies 
Two reviewers (CM and TM) independently evaluated the risk of bias 
of the included studies, reaching consensus in all evaluations (Fig. 2). 
Most studies showed a predominance of moderate to serious risk of bias 
in their risk assessment. Among 47 studies included in quality assess-
ment, only 5 (10.6%) had a global low risk of bias and 7 (14.9%) were 
considered critical. The dimension found to have the highest risk of bias 
concerned measurement of outcomes and missing data (detailed eval-
uation in supplementary Appendix S2 – “Quality Assessment and Risk of 
Bias of included studies”). 
3.4. Determinants of adherence 
The determinants of adherence mostly addressed were: age, gender, 
smoking habits, professional situation, disease knowledge/literacy, ed-
ucation, time since diagnosis, outpatient clinic visits, comorbidities 
(such as obesity, diabetes or cancer), history of past exacerbations, drugs 
and inhalers used, cognitive performance, disease severity and family 
income. 
Thirty-three studies were eligible for data extraction, reporting data 
from 44908 participants, and allowing the conduction of meta-analysis 
of the association between determinants and the risk good adherence to 
inhaled therapy. Detailed information on meta-analysis for each main 
determinant of interest is available at supplementary Appendix S4 – 
“Complete data meta-analysis”. 
Overall, significant trends were observed towards an increased or 
decreased risk for adherence. Fig. 3 reports the main findings from the 
performed meta-analysis. Therefore, the following determinants 
revealed to be significantly associated to good adherence on the pooled 
estimations: older age [RR = 1.07 (1.03–1.10); I2 = 94; p < 0.0001]; 
having good disease knowledge/literacy [RR = 1.37 (1.28–1.47); I2 =
14; p = 0.33]; obesity [RR = 1.30 (1.12–1.50); I2 = 0; p = 0.37]; having 
a good cognitive performance [RR = 1.28 (1.17–1.40); I2 = 0; p = 0.62] 
and having a higher income [RR = 1.63 (1.05–2.56); I2 = 0; p = 0.52]. 
On the other hand, the following determinants were associated to a poor 
predictive adherence: being employed [RR = 0.87 (0.83–0.90); I2 = 0; p 
= 0.76] and using multiple drugs/inhalers [RR = 0.81 (0.79–0.84); I2 =
0; p = 0.80]. 
Subgroup analysis revealed that smoking exposure (active, past or 
passive) is associated with good adherence on European studies only 
[RR = 1.32 (1.10–1.59); I2 = 0; p = 0.50]. Previous exacerbations 
revealed to be associated with better adherence on one single studies 
with Asthma patients, developed on North America [RR = 1.52 
Fig. 2. Risk of Bias assessment in included studies according to an adaptation of the GRADE quality assessment tool.  
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(1.16–1.98)], but with poor adherence in two studies performed in 
Europe with COPD patients [RR = 0.60 (0.36–0.99); I2 = 88; p = 0.003]. 
Also, regarding “older age” as a determinant for good adherence, that 
was found mostly in studies performed in adult populations, while in 
elderly populations the trend was the opposite but not significant. 
Additional sensitivity analysis revealed no significant changes of the 
risk estimates regarding other variables of interest, such as for publi-
cation year, study design, risk of bias assessment, study dimension/ 
sample size, diagnosis included, or types of instruments used to measure 
adherence. Detailed date is available at supplementary Appendix S3 – 
“Complete data of selected studies”. 
No data were available to perform subgroup analysis according to 
different types of inhalers or therapies used, adherence behaviour 
assessed (initiation, implementation or persistence) and adherence 
interface level (patient, provider or health service). 
4. Discussion 
4.1. Summary of key findings 
Adherence to therapy has been a challenge for many years, and 
several factors have been reported to affect adherence on chronic con-
ditions [71,72]. This systematic review is the first to address, at a global, 
comprehensive, and integrated level, the main determinants of adher-
ence to inhalation therapy in patients with COPD and/or Asthma, and to 
quantify the associated risks. 
These results show that the major determinants associated with 
better adherence were higher income (63% in mean relative risk in-
crease), high degree of literacy (37% increase), obesity (30% increase), 
good cognitive performance (28% increase), and older age (7% in-
crease). On the other hand, being employed was associated with a 
decreased risk for adherence (23% in mean relative risk decrease) as 
well as using multiple drugs/inhalers (29% decrease). In addition, 
subgroup analysis revealed that smoking habits are also associated with 
an increased risk for adherence in European countries (32% increase), 
and the gender woman with lower adherence in Asthma (21% decrease). 
Regarding the presence of previous exacerbations, in Asthma it might be 
associated with better adherence, while in COPD it might be associated 
with lower adherence. 
One study reported a greater adherence in dry powder inhaler users 
compared to pressurized metered dose inhaler users, however, it was not 
sufficient to be included in the meta-analysis [57]. 
Nevertheless, no relevant influence on the risk for better adherence 
was found considering professional situation, education, time since 
diagnosis, number of outpatient clinic visits, having other comorbidities 
(such diabetes or cancer) or disease severity stage. 
4.2. Strengths and limitations of the review 
Throughout this review no significant inequities between most of the 
studies were found, despite the high methodological heterogeneity and 
the diversity of applied scales among them. Most included studies have 
poor methodological quality and a high risk of bias, which places a 
limitation on the confidence in the reported results. Another major 
limitation was the heterogeneity present in the scales and instruments 
used to measure adherence, as well as to report and measure the 
determinants. 
Considering adherence itself, different methods were used to mea-
sure and define it. Most used objective measures and defined “good 
adherence” in a dichotomous way, to establish its association to the 
potential determinants. We highlight the fact that the majority of studies 
defined good adherence as “never or rarely forgetting to take a medi-
cation”, with similar cutoffs applied (about 70–80%), either to validated 
questionnaires, electronic records or self-reporting unspecific scales. 
Therefore, we find it less likely to consider a significant bias upon this 
definition. 
Moreover, the methods used to define the determinants were also 
variable. This variety, as well as the high standards defined for “good 
adherence”, means that the reported risk estimations may, at some 
extent, not faithfully represent the environment in the "real world". This 
may also explain the significantly high heterogeneity found in most 
pooled estimations as saw in the I2 values. As an example, age was 
Fig. 3. Forest plot of results on the risk of good adherence to inhaled therapy according to the reported determinants and the most relevant sub-group analysis. All 
determinants are ordered by their RR mean estimate, except for specific sub-group analysis that revealed statistically relevant estimates (signalled with the 
arrowhead mark). I2 - Heterogeneity. 
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reported by several studies as a dichotomous variable using different 
cutoffs, such as 50, 60 or 65 years; therefore, a single cutoff for the 
pooled risk estimation can not be established. That may be the reason 
why “older age” was detected as a significant predictor for better 
adherence in studies with adult populations, while in studies with 
elderly participants the trend was not significantly different. For such 
populations, other factors may also be involved in adherence beside 
objective and sociodemographic characteristics [11]. Moreover, obesity 
was reported only by two studies as being associated to adherence, but 
only one study [43] defined it objectively as body mass index ≥30 
kg/m2 or by the presence of a clinical diagnosis on the participant’s 
record. There is though the doubt whether a slighter overweight may 
also influence adherence patterns, or even if obesity is playing a role as a 
surrogate or confounding for adherence, considering that such patients 
may at some extent, need for more (and be more exposed) to accurate 
and persuasive clinical and educational interventions. The same limi-
tation may be applied to family income, where most studies used the 
national mean family income as the main cutoff, but this may differ 
significantly across different countries. Cognitive performance for 
instance, was defined in most studies in a homogeneous way, as the 
presence/absence of cognitive impairment, but different scales were 
used for cognitive assessment, such as Mini Mental State Examination, 
Montreal Cognitive Assessment Test and other type of skills and memory 
tests. Other determinants were reported with a better homogeneity, such 
as higher educational attainment, which was defined in almost every 
study with the cutoff in the secondary school level. 
Additionally, many studies did not assess the association between 
determinants and adherence with multivariate analysis techniques, nor 
were adjustments made to confounding factors, leading to a large bias in 
the obtained results. For this reason, the estimations resulted in a 
combination of adjusted and unadjusted risk ratios. 
However, the methodological quality applied throughout the review 
must be highlighted, in accordance with the PRISMA recommendations 
(Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 
[21] and compelling on a well-structured method. A broad, but con-
crete, study inclusion criteria (PICO) was designed, reaching consensus 
among all reviewers on a rigorous way, and achieving a careful final 
approach to the results. The inclusion of broad criteria allowed to 
develop a highly comprehensive review with a significant diversity of 
determinants included, with more generalised results. In addition, 
regardless of the limitations pointed out, some of the pooled results 
revealed significant risk associations, either with precise confidence 
intervals, but also of great magnitude of effect, which reinforces the 
confidence of such estimates. Studies in different languages were also 
included, to prevent the imposition of a linguistic barrier and bias. 
Overall, there were significant heterogeneity on the studies meth-
odologies and some estimates was based on few studies, for which the 
risk of bias is moderate to severe. Nevertheless, some determinants 
revealed narrow estimates and strong magnitude on their pooled risk 
ratio, such as “literacy”, “being employed” and “cognitive performance”. 
Considering that, the overall confidence of the results is low, but for 
these specific determinants it may be moderate. 
4.3. Comparison with previous studies 
Inhaled therapy adherence is a topic with limited available studies so 
far [73]. For that reason, we find this review relevant and timely, 
addressing this important gap. 
In the scope of inhalation therapy, previous work focused on aspects 
related to users’ "beliefs" (psychological and subjective determinants). 
However, it does not address all other sociodemographic determinants 
that are considered to be key issues that affects patient adherence [14]. 
In the present review, there were also several studies addressing aspects 
of a more subjective character, such as beliefs about medications and 
patients’ perceptions about diseases. Yet, their characteristics and the 
data reported hampered the ability to include them in the meta-analysis. 
One study demonstrated that perceptions of behavior are better pre-
dictors than sociodemographic ones, reinforcing the paramount di-
versity of factors that should be considered in this type of reviews [74]. 
Another review, on Asthma patients, ended up detecting only age as 
a relevant determinant of adherence. Authors point out the significant 
heterogeneity of the included studies as the main limitation [15]. This 
limitation is also highlighted in the present review. Nevertheless, its 
scope is broader because it included studies on Asthma and COPD and 
reported approximate risk estimations. In fact, in COPD, the patients’ 
characteristics and the used medication are also considered to be key 
factors of adherence to therapy, as revealed by previous works [75]. 
Some interventional studies (with ICS only) tried to improve 
adherence, but without effective results. This might be due to external 
barriers and other key determinants [76] as highlighted by this work. 
GINA and GOLD guidelines have been, since many years, pointing 
out the importance of patients’ determinants on the risk for inhaled 
therapy adherence [1,2]. However, they are unspecific and don’t 
consider such determinants in a global context, regardless the inhaler 
technique used. Some of those highlighted determinants are the type 
and regimen of medication, the difficulty in handling the device due to 
pathologies such as arthritis, the frequency of intake on the same day, 
and the use of different/multiple devices. They also mention the 
importance of unintended factors (e.g. the poor understanding of the 
instructions given to patient, forgetfulness, the absence of a daily routine 
and the cost), but also intentional factors (e.g. the perception that 
treatment is unnecessary, the denial of asthma or its treatment, inap-
propriate expectations, concerns about adverse effects, dissatisfaction of 
caregivers, stigma, cultural and religious issues and costs). GOLD also 
points out the use of multiple devices, older age and the lack of educa-
tion on inhaler performance as key factors for COPD inhaled poor 
adherence. 
4.4. Interpretation and implications of the findings 
Further research must be carried out to clarify the influence of 
sociodemographic and psychological determinants on adherence to 
inhaled therapy, mainly to access their synergic or collinear effects on a 
long-term scope. Some of those factors may at some extent, affect the 
patient’s behavior regarding the disease and its outcomes. That may 
explain the influence found in our review between “having previous 
exacerbations” and a better adherence in Asthma, but worse adherence 
in COPD. Previous works have also found a similar trend in Asthma [77], 
and, therefore, future studies should address this potential causal rela-
tionship. Moreover, ageing itself may have a different effect on adher-
ence during adulthood (improving it) then compared to geriatric age 
(decreasing it), and therefore needs further research. 
These results highlight the need to improve clinical guidelines and 
practice, in order to address such determinants in patients with Asthma 
and COPD, thus, increasing the rates of adherence to inhalation therapy. 
This review brings new evidence to be considered and, possibly, to be 
included in an upcoming review of GINA and GOLD guidelines, where 
new sociodemographic determinants should be considered. 
Another relevant aspect that may be addressed in the future is to 
distinguish between factors associated with non-adherence at the pa-
tient, provider, and system level, as well as at different temporal stages 
(initiating, implementing, and persisting). The studies performed so far 
have not provided enough information to distinguish such interface 
levels from each other, as all the reported estimations were at a patient 
level and patient centered. Nevertheless, some determinants for adher-
ence hereby reported are more related to patients, and others to pro-
viders or to the system/society itself, but no confident conclusions can 
be established about their distinction. 
Further studies should be carried out in developing countries. The 
scarcity of research in these countries is delaying the implementation of 
effective interventions and adherence measures, where poor adherence 
prevails due to the fact that the determinants in these populations are 
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not certainly known [78]. 
Subsequently, it would be important to assess other specific adher-
ence determinants, such as the type of inhaler used (dry powder inhaler 
versus pressurized devices) [57], or even different patterns between 
Asthma and COPD patients. The same applies to employment (hereby 
associated with a decreased risk for adherence), where private 
insurance-based healthcare systems may play a different role than 
compared to those based on national social health services [79]. Also, 
smoking habits have been identified to be related to adherence, but 
previous studies found opposite results, and this has been pointed out as 
a potential confounding effect, as smoking may be a proxy for other 
related behavioral and lifestyle aspects (i.e. anxiety) [80,81]. 
At the methodological level, previous studies have also pointed out 
the need for an harmonisation and padronisation of the exposure and 
outcome assessment, namely the tools used to measure adherence, but 
also the way that all determinants are measured and reported [15]. This 
will allow future systematic reviews to carry out more accurate pooled 
risk estimations. Several methods may be used to measure adherence, 
such as through pill counting, self-report, pharmacy refill accounting, 
electronic monitoring, measurement of blood levels of drugs and even 
frequent observation by healthcare professionals [82]. Nevertheless, 
some of them are complex or have significant costs, and therefore, there 
is the need for a more global, uniform, and consensual method. In this 
systematic review no relevant differences were found on the risk asso-
ciations of all determinants, when comparing different methods to 
measure adherence. At some extent this points out the need for future 
studies comparing different methods to access adherence in real world. 
Future studies should be designed on a longitudinal cohort base, with 
long-term follow-up, in order to assess these causal relationships over 
time, to control for potential confounders, and to access the risk of 
synergic or collinear effects. Also, psychological and cultural factors 
must be addressed in future studies, considering their important di-
mensions in the holistic approach to patients adherence [83]. 
This systematic review presents a wide, inclusive, and comprehen-
sive approach, including studies from all over the world and settings, 
and therefore we find the results timely and generalizable to real world. 
This highlights the importance for clinicians to focus their interventions 
on key factors of adherence to achieve optimal efficacy, regardless of 
their context. 
Finally, by identifying factors related to adherence, this systematic 
review highlights the need for future interventions that may ultimately 
modify them, such as employment, literacy, obesity, cognitive perfor-
mance, and this should be addressed not only by future interventional 
studies, but also on a national and global scale of health policies. 
5. Conclusion 
Adherence to inhaled therapy is the cornerstone of Asthma and 
COPD clinical control and some determinants may be significantly 
associated with better adherence, such as higher income, high degree of 
literacy, obesity, good cognitive performance and older age. On the 
other hand, being employed and using multiple drugs/inhalers was 
associated with decreased adherence. Smoking patterns and gender may 
also play an important role, but uncertainty remains. 
Asthma and COPD guidelines should give a reinforced attention to 
these determinants, recommending their assessment in every appoint-
ment. Further longitudinal, well-designed cohorts with long-term 
follow-up should be developed in order to clarify such causal effects. 
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Asthma bronchiale - versorgung unter Alltagsbedingungen in der pneumologischen 
Praxis, Pneumologie 68 (5) (2014) 315–321, https://doi.org/10.1055/s-0034- 
1365285. 
[37] V. Plaza, et al., Impact of patient satisfaction with his or her inhaler on adherence 
and asthma control, Allergy Asthma Proc. 39 (6) (2018) 437–444, https://doi.org/ 
10.2500/aap.2018.39.4183. 
[38] D. Ierodiakonou, et al., Adherence to inhalers and comorbidities in COPD patients. 
A cross-sectional primary care study from Greece, BMC Pulm. Med. 20 (1) (2020) 
1–10, https://doi.org/10.1186/s12890-020-01296-3. 
[39] M. Olszanecka-Glinianowicz, A. Almgren-Rachtan, The adherence and illness 
perception of patients diagnosed with asthma or chronic obstructive pulmonary 
disease treated with polytherapy using new generation Cyclohaler, Postep. 
Dermatologii i Alergol. 31 (4) (2014) 235–246, https://doi.org/10.5114/ 
pdia.2014.45070. 
[40] B. Sleath, et al., Reported problems and adherence in using asthma medications 
among adolescents and their caregivers, Ann. Pharmacother. 52 (9) (2018) 
855–861, https://doi.org/10.1177/1060028018766603. 
[41] S.L. Janson, G. Earnest, K.P. Wong, P.D. Blanc, Predictors of asthma medication 
nonadherence, Heart & Lung J. Acute Crit. Care 37 (3) (2008) 211–218, https:// 
doi.org/10.1016/j.hrtlng.2007.05.014. 
[42] O. Turan, P.A. Turan, A. Mirici, Parameters affecting inhalation therapy adherence 
in elderly patients with chronic obstructive lung disease and asthma, Geriatr. 
Gerontol. Int. 17 (6) (2017) 999–1005, https://doi.org/10.1111/ggi.12823. 
[43] A. Zucchelli, et al., Adherence to COPD free triple inhaled therapy in the real 
world: a primary care based study, Clin. Res. J. 14 (8) (2020) 732–739, https://doi. 
org/10.1111/crj.13190. 
[44] C.C. Emilio, et al., Is a low level of education a limiting factor for asthma control in 
a population with access to pulmonologists and to treatment? J. Bras. Pneumol. 45 
(1) (2019) 1–5, https://doi.org/10.1590/1806-3713/e20180052. 
[45] D. Price, D.L. Keininger, B. Viswanad, M. Gasser, S. Walda, F.S. Gutzwiller, Factors 
associated with appropriate inhaler use in patients with COPD – lessons from the 
REAL survey, Int. J. COPD 13 (2018) 695–702, https://doi.org/10.2147/COPD. 
S149404. 
[46] J. George, D.C.M. Kong, R. Thoman, K. Stewart, Factors associated with medication 
nonadherence in patients with COPD, Chest 128 (5) (2005) 3198–3204, https:// 
doi.org/10.1378/chest.128.5.3198. 
[47] K.C. Chiu, et al., Patients’ beliefs and behaviors related to treatment adherence in 
patients with asthma requiring maintenance treatment in Asia, J. Asthma 51 (6) 
(2014) 652–659, https://doi.org/10.3109/02770903.2014.898772. 
[48] M. Takemura, et al., Optimal cut-offvalue and clinical usefulness of the Adherence 
Starts with Knowledge-12 in patients with asthma taking inhaled corticosteroids, 
J. Thorac. Dis. 9 (8) (2017) 2350–2359, https://doi.org/10.21037/ 
jtd.2017.06.115. 
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